Healthcare
Merck KGaA(MKGAF)
Live Price
Offline$149.28
-4.99% today
1Y Change
+18.57%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $47.85B
- Revenue Growth
- -0.3%
- EPS Growth
- -6.1%
- Dividend Yield
- 2.0%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Merck KGaA (MKGAF) is a Healthcare stock with a market cap of $47.85B and listed on OTC. The stock last traded around $149.28 and up 18.6% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of -0.3%, EPS growth of -6.1%, a dividend yield of 2.0%. What stands out right now is revenue -0.3%, EPS -6.1%, free cash flow -2.3% with operating margin 20.2% and ROIC 7.6%. The dividend is present but secondary, with a yield around 2.0%. Valuation is more restrained than many high-expectation growth names at P/E 18.3 and price/sales 2.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MKGAF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-0.3% vs +7.6% peer median
Operating Margin
Near sector median
+20.2% vs +19.4% peer median
P/E
Below sector median
18.3 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -0.3% and EPS is at -6.1%, with operating margin around 20.2%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.0%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | -3.0% | -3.0% | +9.3% |
2026 Mar 5, 2026 | -3.5% | -3.3% | -6.7% | -4.3% |
2025 Nov 12, 2025 | -6.6% | +8.5% | +2.2% | +9.1% |
Benchmark Edge
MKGAF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MKGAF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MKGAF Max Drawdown
-24.31%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MKGAF and SPY.
Company Overview
Merck KGaA
Other OTC
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. The Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
- Leadership
- Belen Garijo Lopez
- IPO Date
- Aug 3, 2012
- Employees
- 59.0k
- Street Address
- Frankfurter Strasse 250
- Mailing
- Darmstadt, 64293
- Region
- Darmstadt, DE
- Reporting Currency
- USD
- Investor Line
- 49 6151 72 0
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 18.3
- EV/EBITDA
- 8.7
- Price/Sales
- 2.3
- Price/Book
- 1.7
Growth
- Revenue
- -0.3%
- EPS
- -6.1%
- Free Cash Flow
- -2.3%
Profitability
- Gross Margin
- 58.5%
- Operating Margin
- 20.2%
- Net Margin
- 12.4%
- ROE
- 9.0%
- ROIC
- 7.6%
Balance Sheet
- Debt/Equity
- 0.42
- Current Ratio
- 1.46
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.